☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Rosiglitazone on Panorama

Rosiglitazone (Avandia®, Avandamet®) will be the subject of the current affairs programme Panorama tonight. In particular the programme appears to be drawing attention to the cardiovascular risks of the drug and also to the ongoing safety review.

The European Medicines Agency has announced an additional meeting to review the complex data in order to finalise the review of rosiglitazone in time for the next scheduled meeting of 20-23 September 2010.

Panorama also claims that the Commission for Human Medicines, an advisory committee to the Medicines and Healthcare product Regulatory Agency (MHRA), voted unanimously in July for rosiglitazone to be withdrawn from the market. The contents of these meetings normally remain confidential until a full review is completed since it may not be in the public interest to release such information until the regulatory process being completed.

Action: Clinicians should be aware of this programme. Patients who are taking rosiglitazone currently may seek advice or request an alternative.

Share 'Rosiglitazone on Panorama' by emailShare 'Rosiglitazone on Panorama' on FacebookShare 'Rosiglitazone on Panorama' on TwitterShare 'Rosiglitazone on Panorama' on LinkedInShare 'Rosiglitazone on Panorama' on reddit


One Comment to “Rosiglitazone on Panorama”

  1. All glitazones should be withdawn from the market, see "Do not use glitazones either alone or in combination for treatment of diabetes" in
    Prescrire International 2008 ; 17 (97) : 189

    Comment by Christophe Kopp — September 6, 2010 #

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.